⌕
Septerna · SEPN · Nasdaq
Tenet 54 · Mixed
Compare
$40.02−3.96%At closeTenet 54 · Mixed
$40.02−1.65 (−3.96%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Septerna (SEPN) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Seeking AlphaNov 16, 2026 · 12:52 ET
Septerna, Inc. (SEPN) Presents at UBS Global Biopharma Conference 2026 Transcript

Septerna, Inc. ( SEPN ) UBS Global Biopharma Conference 2026 November 16, 2026 9:00 AM EST Company Participants Jeffrey Finer - Co-Founder, CEO & Director Liz Bhatt - President & COO Conference Call Participants Alice Ne…

● Seeking AlphaNov 11, 2026 · 05:10 ET
Septerna: The SEP-479 Readout Could Unlock Further Upside

Septerna, Inc. is positioned for near-term value creation, with SEP-479 as the primary catalyst and a strong cash runway into 2029. SEP-479's Phase 1 readout in 1Q27 could provide the first meaningful clinical validation…

● Zacks Investment ResearchNov 9, 2026 · 18:35 ET
Septerna, Inc. (SEPN) Reports Q3 Loss, Lags Revenue Estimates

Septerna, Inc. (SEPN) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.09 per share a year ago.…

● GlobeNewsWireNov 9, 2026 · 16:01 ETCOMPANY'S OWN WORDS
Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results

Phase 1 Clinical Trial for PTH1R Agonist SEP-479 Ongoing; SAD / MAD Data Expected in Q1 2027 Plans to Initiate Phase 1 Clinical Trial of Newly Selected Oral TSHR NAM Development Candidate SEP-204 in Q1 2027 Cash Position…

● GlobeNewsWireNov 4, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting

Potent, selective TSHR NAM with pre-clinical activity demonstrated across biochemical, thyroid and ocular endpoints Favorable PK profile anticipated to support once-daily oral dosing in humans Phase 1 clinical trial init…

● GlobeNewsWireNov 3, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Septerna to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announc…

● Defense WorldOct 20, 2026 · 04:22 ET
Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 4,000 Shares of Stock

Septerna, Inc. (NASDAQ: SEPN - Get Free Report) COO Elizabeth Bhatt sold 4,000 shares of the company's stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $37.41, for a total …

● Defense WorldSep 28, 2026 · 06:15 ET
CRISPR Therapeutics (NASDAQ:CRSP) & Septerna (NASDAQ:SEPN) Head-To-Head Survey

Septerna (NASDAQ: SEPN - Get Free Report) and CRISPR Therapeutics (NASDAQ: CRSP - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of …

● Defense WorldSep 24, 2026 · 02:29 ET
Analyzing Valneva (NASDAQ:VALN) and Septerna (NASDAQ:SEPN)

Valneva (NASDAQ: VALN - Get Free Report) and Septerna (NASDAQ: SEPN - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of t…

● Defense WorldSep 22, 2026 · 06:15 ET
Comparing WAVE Life Sciences (NASDAQ:WVE) and Septerna (NASDAQ:SEPN)

Septerna (NASDAQ: SEPN - Get Free Report) and WAVE Life Sciences (NASDAQ: WVE - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on…

● Defense WorldSep 16, 2026 · 04:37 ET
VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 13,300 Septerna, Inc. $SEPN

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Septerna, Inc. (NASDAQ: SEPN) during a recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fu…

● GlobeNewsWireSep 10, 2026 · 16:00 ETCOMPANY'S OWN WORDS
Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), today announced that the Company granted a non-qualified stock option to purchase up to 275,000 shares of the Company's commo…

● GlobeNewsWireSep 1, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Septerna to Participate in Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announ…

● Seeking AlphaAug 28, 2026 · 18:00 ET
Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term

Septerna, Inc. has surged >315% since May 2025, driven by its GPCR-focused drug discovery and a high-profile collaboration with Novo Nordisk. The SEPT partnership with NOVO targets GLP-1, GIP, and glucagon receptors, wit…

● GlobeNewsWireAug 25, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announc…

No upcoming events in the feeds.

NVDA31−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just SEPN · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.